Guardant Health , Inc. (NASDAQ:GH), a $4.4 billion market cap company, recently saw a stock transaction involving its director, Tariq Musa. According to a filing with the Securities and Exchange Commission, Musa sold 2,320 shares of Guardant Health common stock on December 13, 2024, at a price of $35 per share, totaling $81,200. Following this sale, Musa holds 2,676 shares directly. The stock has shown strong momentum, gaining over 31% year-to-date. According to InvestingPro analysis, the company maintains a GOOD financial health score, with analysts setting price targets ranging from $34 to $60.
Additionally, on December 15, 2024, Musa acquired 250 shares through the exercise of restricted stock units, which were granted on March 6, 2023, and vest over a four-year period. These transactions were completed under a prearranged trading plan. After these transactions, Musa's total direct ownership stands at 6,746 shares. For deeper insights into Guardant Health's valuation and additional ProTips, including analyst revisions and financial metrics, visit InvestingPro, where you'll find comprehensive research reports and expert analysis.
In other recent news, Guardant Health reported its financial results for the third quarter of 2024. The earnings call, led by Zarak Khurshid, Vice President of Investor Relations, and participated by Co-CEOs Helmy Eltoukhy and AmirAli Talasaz, as well as CFO Mike Bell, highlighted the company's performance. The management team discussed non-GAAP financial measures and emphasized the potential discrepancies between projected and actual results due to inherent risks and uncertainties.
Guardant Health also clarified that it does not intend to update or revise financial projections or forward-looking statements unless required by law. This statement underscores the unpredictable nature of the market and the company's financial performance. Despite the lack of specific financial details such as revenue or earnings per share in the summary, the absence of any mentioned financial misses suggests that Guardant Health may have met its expectations for the quarter.
These are the recent developments from Guardant Health, and further details can be found in the company's official press release and SEC filings. It's important to note that the company reaffirmed its commitment to accurate financial reporting and transparency to its investors during the call, acknowledging the limitations and potential changes that could arise in the future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.